Tuesday, February 23, 2021

AstraZeneca jabs less effective against South African strain, study finds

But the vaccine developers in Britain say informally the results offer some hope that the vaccine could prevent deaths from the variant.

Other News

Youngest woman to row solo across an ocean

She wanted to inspire young people, especially girls, to try amazing things.

Court will decide whether Parliament can or cannot stand suspended

The court adjudicates solely on constitutional provisions and not on why schools can re-open but Parliament cannot convene.

US airs concerns over govt’s plan to deport 1,200 to Myanmar

The migrants, who include members of vulnerable minorities, are set to be repatriated aboard three vessels sent from Myanmar, where the military seized power at the start of February.

2,192 kes baru Covid-19, 3,414 pulih, 6 lagi kematian dilaporkan

Kes aktif dengan kebolehjangkitan pula berjumlah 32,076.

New cases dip to 2,192 as recoveries stay ahead

3,414 recoveries, six more deaths.

The Oxford/AstraZeneca vaccine fails to prevent mild and moderate cases of the South African coronavirus strain, researchers said Sunday.

The University of Witwatersrand, Johannesburg, which conducted the trial, said in a statement that the vaccine “provides minimal protection against mild-moderate Covid-19 infection” from the variant.

But in a full paper due to be published on Monday, AstraZeneca said that none of the 2,000 participants developed serious symptoms.

That could mean it will still have an effect on severe disease, although there is not yet enough data to make a definitive judgement.

The data, which has not yet undergone peer review, “appear to confirm the theoretical observation that mutations in the virus seen in South Africa will allow ongoing transmission of the virus in vaccinated populations”, it said.

“Protection against moderate-severe disease, hospitalisation or death could not be assessed in this study as the target population were at low risk.”

But the vaccine developers in Britain said informally the results offered some hope that the vaccine could prevent deaths from the variant.

“We may not be reducing the total number of cases but there is still protection against deaths, hospitalisations and severe disease,” said Sarah Gilbert, who led the development of the vaccine with the Oxford Vaccine Group.

It could also be “some time” before they determine its effectiveness for older people in fighting the strain, which is a growing presence in Britain, she told BBC television.

“We might have to put it together from a number of studies,” she said.

Researchers are currently working to update the vaccine, and “have a version with the South African spike sequence in the works” that they would “very much like” to be ready for the autumn, she added.

UK vaccines minister Nadhim Zahawi said the government’s strategy to combat the spread of the strain was to continue with its mass vaccination programme “as rapidly as possible” as well as “hyper-local surge testing” where it is detected.

Britain is in the midst of a massive vaccination drive, which it sees as its way out of one of the worst outbreaks in the world that has seen more than 112,000 fatalities among those testing positive for the virus.

It has so far vaccinated more than 11 million people using either the Pfizer/BioNTech or Oxford/AstraZeneca shots.

The AstraZeneca vaccine has been the source of an ugly row with the European Union, which is angry that the Anglo-Swedish firm was unable to meet the delivery target agreed with Brussels.

France, Germany and Switzerland are also among countries to recommend the vaccine not be used for the elderly due to a lack of data.

Follow us on Telegram for the latest updates: https://t.me/malaysianow

Subscribe to our newsletter

To be updated with all the latest news and analyses.

Related Articles

New cases dip to 2,192 as recoveries stay ahead

3,414 recoveries, six more deaths.

Economy to recover this year on effective vaccine deployment, says World Bank

The World Bank expects Malaysia's economic growth this year to range from 5.6 to 6.7%.

Air New Zealand to trial digital Covid-19 ‘vaccination passport’

Air New Zealand will trial a digital travel pass to give airlines and border authorities access to passenger health information, including their Covid-19 vaccination status.

Prayer has not defeated Covid-19, Tanzanian president finally confesses

A number of countries have reported that visitors arriving from Tanzania have tested positive for the virus.

High-risk teachers may be included in Phase 1 of vaccination programme

Deputy Education Minister 1 Muslimin Yahaya says discussions are underway with the science, technology and innovation ministry.